CAS: 4113-04-6; 6-Quinolinecarboxaldehyde

相似化合物

73987-38-9 38896-30-9 10349-57-2

上下游产品

CAS号100516-88-9 6-羟甲基喹啉 | CAS号91-62-3 6-甲基喹啉 | CAS号10349-57-2 6-喹啉甲酸 | CAS号67-66-3 氯仿 | CAS号858784-67-5 N-(quinoline-6-... | CAS号872264-38-5 6-(二溴甲基)喹啉 | CAS号5382-47-8 喹啉-6-碳酰肼 | CAS号73987-38-9 6-喹啉甲酸乙酯 | CAS号73013-68-0 6-乙酰基喹啉 | CAS号100516-88-9 6-羟甲基喹啉 | CAS号3608-83-1 6-Quinolinecarb... | CAS号10349-57-2 6-喹啉甲酸 | CAS号89060-19-5 1-quinolin-6-yl... | CAS号54-82-0 4-(2-quinolin-6...

6-羟甲基喹啉置于戴斯-马丁氧化剂体系中,用 二氯甲烷,水 作为反应溶剂,以85%的收率获得产物喹啉-6-甲醛
参考文献:一类新的非肽类 Cruzain 抑制剂的鉴定
标题:一类新的非肽类 Cruzain 抑制剂的鉴定
摘要:Cruzain 是克氏锥虫的主要半胱氨酸蛋白酶,它是南美锥虫病的病原体,是开发新化疗的有希望的靶点.为了开发有效的 Cruzain 非肽抑制剂,使用底物活性筛选 (Sas) 方法筛选最初设计用于靶向同源人蛋白酶组织蛋白酶 S 的蛋白酶底物库.接下来使用基于结构的设计来进一步改进底物通过在 Cruzain 的 S3 口袋中引入额外的结合相互作用来提高切割效率.然后通过引入基于半胱氨酸蛋白酶机制的药效团将优化的底物转化为抑制剂.抑制剂 38 被确定是可逆的,即使它掺入了乙烯基砜药效团,该药效团已被充分证明可以对肽抑制剂产生不可逆的 Cruzain 抑制作用.先前未探索的 β-氯乙烯基砜药效团提供了导致开发有效的不可逆酰基和芳基氧甲基酮 Cruzain 抑制剂的机理洞察力.对于这些抑制剂,效力不仅仅取决于离去基团 P K A,2,3,5,6-四氟苯氧基甲基酮 54 被鉴定为最有效的抑制剂之一,其二级失活常数为
DOI:10.1021/ja710254M

专利信息

专利号:WO-2023072969-A1
优先权日:2021-10-26
标题 :Imidazolone derivatives as inhibitors of protein kinases in particular dyrk1a, clk1 and/or clk4
发明人：DEAU EMMANUEL; GEORGE PASCAL; MEIJER LAURENT; MIEGE FRÉDÉRIC; ARCHAMBAUD SYLVIE
权利人:PERHA PHARMACEUTICALS
摘要:The present invention relates to a compound of formula (I) wherein A, B, C, D and E are selected from the group consisting of =CH- and -N=, R 2 is selected from a hydrogen atom, a (C 1 -C 4 )alkyl group and a (C 3 -C 6 )cycloalkyl group, R 1 represents a (C 4 -C 6 )alkyl group, a (C 3 -C 8 )cycloalkyl group, a bridged (C 6 -C 10 )cycloalkyl group, a fused phenyl group, a substituted phenyl group, a R'-L- group, wherein L is either a single bond or a (C 1 -C 3 )alkanediyl group, and R' represents, a (C 3 -C 8 )heterocycloalkyl group, or a (C 3 -C 8 )heteroaryl group, or a R'-L- group wherein L is a (C 1 -C 3 )alkanediyl group, and R' is a an optionally substituted phenyl group or any of its pharmaceutically acceptable salt. The present invention further relates to a composition comprising a compound of formula (I) and a process for manufacturing said compound as well as its synthesis intermediates. It also relates to said compound for use as a medicament, in particular in the treatment and/or prevention of cognitive deficits and neuroinflammation associated with Down syndrome, Alzheimer's disease, dementia and/or tauopathies; Parkinson's disease; CDKL5 Deficiency Disorder; Phelan-McDermid syndrome; autism; type 1 and type 2 diabetes; abnormal folate and methionine metabolism; tendinopathy and osteoarthritis; Duchenne muscular dystrophy; several cancers; neuroinflammation, anemia, infections and for regulating body temperature.

专利号:US-9884842-B2
优先权日:2013-04-19
标题 :Combretastatin analogs
发明人：PENTHALA NARSIMHA REDDY; CROOKS PETER; SONAR VIJAYAKUMAR
权利人:UNIV ARKANSAS; BIOVENTURES LLC
摘要:The present invention relates novel heterocyclic analogs of combretastatin, their synthesis, and their use as anti-cancer compounds. In particular, compounds of Formula (I), Formula (II), and Formula (V) are provided.

专利号:WO-2024097744-A2
优先权日:2022-11-01
标题 :Dna-compatible wittig olefination of on-dna peptidyl-ylides for development of on-dna peptidomimetics through diversity-oriented synthesis (dos)